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Introduction
In 1969, Liggins found that premature lambs given
glucocorticoids in utero survived longer than untreated
control lambs [1]. Three years later, Liggins and Howie
first used antenatal corticosteroid treatment in pregnant
women to prevent respiratory distress syndrome (RDS)
in preterm neonates, resulting in decreased neonatal
mortality [2]. Subsequently, serial studies have confirmed
the effectiveness of this therapy [3–8]. Additionally,
many randomized or controlled trials have demonstrated
that antenatal corticosteroids reduce the risk of RDS,
intraventricular hemorrhage (IVH), periventricular leu-
komalacia (PVL) and necrotizing enterocolitis (NEC)
[9–11]. However, complications, such as infection, sep-
sis and maternal pulmonary edema, have been noted
in both neonates and mothers [12–14]. We reviewed
articles published from the 1970s to 2004 and discuss
the benefits and risks of antenatal corticosteroids.
Betamethasone vs Dexamethasone
Betamethasone and dexamethasone have generally been
the preferred corticosteroids because of their beneficial
effect on fetal organ development. These agents have
relatively good placental transfer, a long half-life and
duration of activity, identical biologic effects, little min-
eralocorticoid activity, and relatively weak immuno-
suppressive activity [12]. They are almost identical in
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structure, differing only in the _ versus ` position of the
methyl group at position 16. In 1994, the National Insti-
tutes of Health (NIH) recommended either two 12 mg
doses of betamethasone given intramuscularly 24 hours
apart or four 6 mg doses of dexamethasone given
intramuscularly 12 hours apart between 24 and 34
weeks of gestation [12]. Rayburn et al studied beta-
methasone and dexamethasone in pregnant mice and
found subtle differences in memory and behavior in the
offspring. They concluded that betamethasone was bet-
ter than dexamethasone in terms of neurobehavioral
development in mice [15]. Baud et al published a retro-
spective study of 883 infants with gestational ages
between 24 and 31 weeks, and found that betametha-
sone was associated with a lower risk of PVL than dexa-
methasone [16]. Whitelaw and Thoresen reviewed the
literature and recommended betamethasone rather
than dexamethasone for antenatal corticosteroid ther-
apy [17]. However, several prospective randomized tri-
als have revealed that betamethasone has a greater
propensity than dexamethasone to suppress fetal heart
rate and biophysical activity [18–20]. The suppression
is temporary, but awareness of this particular drug-
induced effect is important so that it is not interpreted
as fetal distress requiring immediate delivery.
Fetal Effects
Respiratory distress syndrome
Liggins and Howie performed a randomized controlled
study in 282 mothers and found that betamethasone
12 mg intramuscularly in two doses, 24 hours apart, pre-
vented RDS in their preterm neonates [2]. Babies born
before 34 weeks had a significant reduction in RDS and
neonatal mortality if birth was delayed for at least 24
hours or up to 7 days after completion of the course of
betamethasone, as substantiated by a number of other
studies [3–8].
Ballard et al compared the outcome in 114 infants
with birth weights between 750 and 1,750 g whose moth-
ers received antenatal betamethasone therapy with that
in 138 infants born to untreated mothers [4]. The inci-
dence of RDS after betamethasone was 37.7% com-
pared with 50.7% without treatment. Doran et al per-
formed a double-blind controlled study of antenatal
betamethasone treatment in 137 patients from 24 to
34 weeks of gestation [6]. The incidence of RDS was
less in the treated group (5%) than in the control group
(17%), and neonatal mortality was lower in the treated
group (5%) than in the control group (18%). Young et
al carried out a prospective trial of intravenous dexa-
methasone for prevention of neonatal RDS in 112 moth-
ers compared with 188 untreated controls [7]. In neo-
nates born at 28 to 33 weeks of gestation, the treatment
group had half the perinatal mortality and one-fourth
the incidence of severe RDS seen in the control group.
Crowley et al analyzed data from 12 controlled trials
involving over 3,000 women [21]. They demonstrated
that antenatal corticosteroid administration reduced
the risk of neonatal RDS by 50%, and this benefit was
most obvious when the interval from corticosteroid
treatment to delivery was between 24 hours and 7 days.
Maher et al retrospectively reviewed a group of very
preterm infants born to 432 women who delivered at
26 to 31 weeks [22]. Of these mothers, 67 had received
antenatal betamethasone and 365 had not. When
betamethasone was administered at least 2 days be-
fore delivery, there was a lower incidence of RDS in
both the 26–28-week group (53.9% vs 86.5%) and the
29–31-week group (25.0% vs 59.1%), compared with
the untreated group. In a regression analysis of neo-
nates born between 26 and 31 weeks, the odds ratio
(OR) for RDS after betamethasone treatment was 0.20
(confidence interval [CI], 0.10 to 0.42).
The mechanism by which treatment is thought to
reduce the frequency of RDS is the induction of enzymes
controlling biosynthesis of surfactant in the fetal lung.
Effects of antenatal corticosteroids on the developing
lung include increased tissue and alveolar surfactants,
increased compliance and maximal lung volume, de-
creased vascular permeability, more mature parenchy-
mal structure, enhanced clearance of lung water, en-
hanced response to surfactant treatment and improved
respiratory function [23].
Intraventricular hemorrhage
In 1986, Morales et al carried out a prospective, blinded,
randomized study of antepartum dexamethasone ad-
ministration in 250 women between 28 and 33 weeks’
gestation who had preterm premature rupture of mem-
branes (PPROM) [24]. The dexamethasone-treated
group had a lower incidence of IVH. More recently,
O’Shea et al collected data on 201 neonates with very
low birth weights, and found that maternal treatment
with betamethasone was associated with a decreased
incidence of IVH [25]. During the same period, Garite et
al performed a double-blind clinical trial of antenatal
betamethasone treatment in mothers with intact mem-
branes and threatened premature delivery between 24
and 28 weeks’ gestation [26]. The treatment group of
36 mothers received two 12 mg doses of betametha-
sone, 24 hours apart, while 41 mothers received place-
bo. The incidence of grade 3 (blood acutely distending
the lateral ventricles) and grade 4 IVH (blood within the
ventricular system and parenchyma) was lower in the
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betamethasone-treated group (betamethasone vs place-
bo, 1/31 vs 9/36; p = 0.01). In 2003, Linder et al studied
a cohort of 641 preterm neonates with a birth weight of
less than 1,500 g, of whom 36 had grade 3 or 4 IVH [27].
Risk factors for IVH in this group included early sepsis
and lack of antenatal corticosteroid administration.
Many observers believe that IVH is a consequence of
increased cerebral blood flow to the delicate germinal
matrix capillary network. Corticosteroids induce perina-
tal maturation of the germinal matrix microvascula-
ture, making them more resistant to rupture, thus de-
creasing the risk of IVH [26,28].
Periventricular leukomalacia
PVL is the most frequent cause of cerebral palsy in
children who are born prematurely and is considered a
sonographic marker for cerebral palsy [29,30]. Unlike
IVH, little is known about the relationship between
antenatal glucocorticoids and the incidence of PVL.
Baud et al performed a retrospective analysis of 883
infants born between 24 and 31 weeks of gestation [16].
In this series, 361 mothers received antenatal betametha-
sone, 165 mothers received dexamethasone and 357
mothers did not receive any glucocorticoid. The incidence
of PVL was 4.4% in neonates in the betamethasone
group, 11.0% in the dexamethasone group and 8.4% in
the no-treatment group. Betamethasone was thus
associated with a lower incidence of PVL compared with
no glucocorticoid therapy (OR, 0.5; 95% CI, 0.2–0.9)
and dexamethasone (OR, 0.3; 95% CI, 0.1–0.7).
Canterino et al carried out another retrospective co-
hort study that included 1,161 neonates born between
24 and 34 weeks with birth weights of 500–1,750 g
[11]. They found that neonates of mothers treated with
antenatal betamethasone had a 56% lower risk of PVL
with IVH (OR, 0.44; 95% CI, 0.25–0.77) and a 58%
lower risk of isolated PVL (OR, 0.42; 95% CI, 0.20–
0.88). The physiologic effects of antenatal corticosteroid
administration include accelerated cytodifferentiation,
greater maturity of cerebrovascular endothelial cells
and autoregulation of cerebral perfusion, and increased
activity of antioxidant enzymes, which lessens the risk of
neurologic cell damage [11].
Necrotizing enterocolitis
The pathogenesis of NEC is not well understood. Factors
thought to increase the risk of intestinal injury include
prematurity, enteral feeding, intestinal ischemia and
bacterial colonization [31]. Results vary in studies ex-
amining the effect of antenatal steroid administration
on the incidence of NEC. In 1984, Bauer et al reported
a significantly decreased incidence of NEC (p = 0.002)
in a large multicenter, randomized, blinded trial of ante-
natal corticosteroids, which included 696 mothers and
their 745 infants [32]. They concluded that antenatal
corticosteroid therapy appeared to accelerate intesti-
nal maturation. More recently, Halac et al performed a
study of 466 women in premature labor given either
placebo (n = 256) or betamethasone (n = 210) [33]. The
incidence of NEC was significantly lower in the betameth-
asone group. However, Uauy et al and Wells et al were
not able to demonstrate a decreased risk for NEC after
antenatal steroid therapy [34,35].
Neonatal infection and sepsis
In the systematic review of 3,000 mothers by Crowley
et al, the incidence of neonatal infection was not signi-
ficantly higher in the corticosteroid-treated group than
in the control group [21]. Vermillion et al prospective-
ly studied pregnancies where infants were delivered
between 24 and 34 weeks’ gestation after antenatal
betamethasone administration [13]. A total of 453
mothers were included in this study, of whom 267 re-
ceived a single course of betamethasone (two 12 mg
doses in a 24-hour interval) and 186 received multiple
courses of betamethasone (the same initial single regi-
men and then additional doses before delivery, either as
a single rescue dose within 14 days of the initial course
or as a weekly prophylactic regimen). They concluded
that multiple courses of betamethasone in women de-
livering before 34 weeks of gestation increased the risk
of early-onset neonatal sepsis (OR, 5.00; 95% CI, 1.3–
23.2) and sepsis-related neonatal death (OR, 2.92; 95%
CI, 1.3–6.9).
Neonatal mortality
Given the benefits of antenatal corticosteroid therapy in
reducing the incidence of RDS, IVH, PVL and NEC, we
would expect to see a significant decrease in neonatal
mortality. This is borne out by a number of studies. RDS
is the most acute problem in the very premature infant
and, together with IVH, is a major risk factor for neo-
natal death. In the overview by Crowley et al, the inci-
dence of early neonatal death was significantly lower
in the corticosteroid-treated group than in the con-
trol group (OR, 0.59; 95% CI, 0.47–0.75) [21]. More
recently, Crowley performed a meta-analysis of ran-
domized trials of antenatal corticosteroid therapy pub-
lished between 1972 and 1994, and found that neo-
natal mortality remains substantially lower in infants
 of corticosteroid-treated mothers (OR, 0.60; 95% CI,
0.48–0.76) [10]. Maher et al, in their study of infants
born between 26 and 31 weeks, found that the OR for
neonatal mortality in these very preterm infants after
antenatal betamethasone was 0.14 (95% CI, 0.02–
1.09) [22].
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Long-term adverse effects
Several studies since the 1970s have followed the
development of infants and children for as long as 12
years and have shown no adverse effects of antenatal
corticosteroids on motor skills, language, cognition,
memory, concentration or scholastic achievement [12].
Schaap et al performed a case-control study to evaluate
the effects of antenatal corticosteroid administration
on mortality and long-term morbidity in early preterm
(26–32 weeks’ gestation), growth-restricted neonates
[36]. Both the corticosteroid-treated and control groups
consisted of 62 neonates. Children in the corticosteroid-
treated group were more likely to survive with no disabili-
ty or handicap at 2 years of age (OR, 3.2; 95% CI, 1.1–
11.2). By school age, there were no detectable differences
in behavior, but physical growth in the steroid-treated
group was significantly reduced (OR, 5.1; 95% CI, 1.4–
23.8).
Maternal Effects
Maternal pulmonary edema
An increased risk of maternal pulmonary edema has
been reported when antenatal corticosteroids are
administered in combination with tocolytic agents,
with a reported incidence during co-administration of
steroids and betamimetics of about 5% [14]. Two cases
of pulmonary edema have been reported in women
who had received both corticosteroids and magne-
sium sulfate, an incidence in that series of 1.6% [37]. It
is good to remember that fluid overload, multiple ges-
tations and underlying heart disease are other signifi-
cant precipitating factors for maternal pulmonary ede-
ma. This complication has not been reported when an-
tenatal corticosteroids are administered alone.
Maternal infection
The risk of maternal infection may be increased when
antenatal corticosteroids are used in PPROM [12,38].
In the meta-analysis by Crowley, the OR for maternal
infection in this situation was 1.15 (95% CI, 0.84–
1.57) [10]. In the study by Vermillion et al comparing
single versus multiple courses of betamethasone, the
latter was significantly associated with chorioamnionitis
(OR, 9.96; 95% CI, 2.1–64.6) and endometritis (OR,
3.61; 95% CI, 1.7–8.1) [13].
HELLP syndrome
HELLP syndrome (hemolysis, elevated liver enzymes and
low platelet counts) is a well-recognized complication of
severe pre-eclampsia and eclampsia, and is associated
with increased maternal and perinatal mortality. Dexa-
methasone effectively ameliorates HELLP in antepartum
patients and accelerates postpartum recovery [39,40].
Isler et al demonstrated that intravenously administered
dexamethasone appears to be more effective than intra-
muscularly administered betamethasone for antepar-
tum or postpartum HELLP syndrome [41,42]. It has
been hypothesized that corticosteroids are beneficial
in this entity because of their effects on the systemic
microvasculature, particularly in the hepatic and renal
vascular beds. Nevertheless, further investigation appears
to be warranted to determine the optimal corticosteroid
dose, timing of treatment and route of administration.
Single vs Multiple Courses of Corticosteroids
Many studies have compared the benefits and risks of
a single course versus multiple courses of antenatal
corticosteroid administration, with most indicating a
greater incidence of short- or long-term adverse ef-
fects with multiple courses. These may include neonatal
infection and death, maternal and fetal adrenal sup-
pression, maternal infection, impaired glucose tolerance,
osteoporosis, reduction of neonatal birth weight and
head circumference, and possibly an increased incidence
of neonatal chronic lung disease [13,43–45]. Moreover,
no obvious reduction in RDS, IVH, PVL, NEC and neo-
natal sepsis has been demonstrated in women treated
with repeated courses of corticosteroid therapy [38,
44,46]. Nevertheless, several other studies have reached
opposite conclusions, finding no significant adverse
effects on neonatal birth weight, head circumference, or
neonatal and maternal infection after multiple courses
of corticosteroids [47,48].
Based on the available evidence, the NIH and Gold-
enberg and Wright have concluded that current data
are insufficient to support routine use of repeated or
rescue courses of antenatal corticosteroids [49,50].
They recommend further prospective randomized clini-
cal trials to resolve this question. Nevertheless, many
obstetricians are concerned when the risk for premature
delivery persists after one course of steroids has already
been given, especially if it was given long before 34
weeks’ gestation. Is it safe to forgo further treatment
despite the ongoing risk? Caughey and Parer used
decision analysis to develop a strategy for pregnancies
at risk for preterm delivery between 24 and 34 weeks
[51]. Based on their model, if there is still a potential risk
of preterm delivery subsequent to the first course of cor-
ticosteroids, a second course may be administered 2
weeks later, but no more than two courses should be
given. They also emphasized the need for randomized
clinical trials to assess this strategy.
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Conclusions
The benefits of antenatal corticosteroids in reducing
morbidity and mortality in preterm neonates are clear
and generally outweigh the risks associated with this
therapy. As the benefits are most obvious when the
treatment is given within 1–7 days before delivery, the
main question remaining to be answered is what to do
if steroids have already been given but delivery is delayed
beyond a week after that. At this point, the evidence is
inadequate to give a firm answer, so the decision must
be based on theoretical considerations. It is hoped that
prospective clinical trials will eventually provide adequate
information to answer this question.
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